A randomised trial of population screening for melanoma
Open accessThe DOI matches its Crossref record.
Abstract
Objectives: Melanoma is a significant cause of morbidity and mortality worldwide and incidence is increasing. Survival after treatment is inversely related to the thickness of the tumour at diagnosis. Population screening has the potential to reduce mortality but there is no conclusive evidence of benefit. Such evidence can come best from a randomised trial. Here we describe the design of a community based randomised trial of a population screening programme for melanoma in Queensland, Australia and early results of the first phase of the trial. Methods: A total of 44 communities (aggregate population 560 000 adults aged 30 years or more) will be randomised to receive either a community based screening programme for 3 years or normal practice. The screening programme promotes thorough skin self examination and whole body skin examination by a doctor and provides open access skin cancer screening clinics. In its first phase, the trial is underway in nine intervention and nine control communities. The primary outcome measure is mortality from melanoma during 15 years of follow up. Results: The first phase of the trial has shown the feasibility of implementing a population skin screening programme including regular skin cancer screening clinics, and has shown the strong support of communities and doctors for the programme. There has been a significant 2.5-fold increase in participation in screening in the intervention communities in this first phase after the first 12 months of the trial and no significant increase in participation in screening in control communities during this period. Conclusions: The design of a community based randomised trial of screening for melanoma has been successfully peer reviewed and the intervention has been shown to be feasible in practice. This randomised trial may be one of the last opportunities to develop the evidence required for public health recommendations for population screening for melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Epidemiology of invasive cutaneous melanoma
MacKie, R. M., Hauschild, A., & Eggermont, A. M. M. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp252 · Cited by 405
“A randomised trial of population screening was carried out in small Queensland towns, where some residents were selected for the screening, and compared with control towns, where mass screening was not offered [47, 48].”
Background‘Mind your Moles’ study: protocol of a prospective cohort study of melanocytic naevi
Koh, U., Janda, M., Aitken, J. F., Duffy, D. L., Menzies, S., Sturm, R. A., Schaider, H., Betz-Stablein, B., Prow, T., Soyer, H. P., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2018-025857 · Cited by 36
Self-citationSurvival Is Not the Only Valuable End Point in Melanoma Screening
Curiel-Lewandrowski, C., Kim, C. C., Swetter, S. M., Chen, S. C., Halpern, A. C., Kirkwood, J. M., Leachman, S. A., Marghoob, A. A., Ming, M. E., & Grichnik, J. M. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.3 · Cited by 26
“The Australian clinical trial was designed to detect a 20% reduction in mortality from melanoma during the 15 year intervention period (Aitken et al, 2002).”
Method
Metadata
- Authors
- Aitken, J. F., Elwood, J. M., Lowe, J. B., Firman, D. W., Balanda, K. P., & Ring, I. T.
- Venue
- Journal of Medical Screening
- Publisher
- SAGE Publications
- Published
- 2002-03-01
- Volume
- 9
- Issue
- 1
- Pages
- 33-37
- ISSN
- 0969-1413 (ISSN-L)
- 1475-5793
- OpenAlex
- W1967371534
- Cited by
- 96
- References
- 0
- FWCI
- 3.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.